Hao Zhu

Hao Zhu

Auto-generated profile, based on publicly available information

Hao Zhu

Office of Clinical Pharmacology Office of Translational Sciences, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2022 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
RMRajanikanth Madabushi
Rajanikanth Madabushi
PSPaul Seo
Paul Seo
LZLiang Zhao
Liang Zhao
MTMillion Tegenge
Million Tegenge
HZHao Zhu
Hao Zhu

3 January 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
KNKunal Naik
Kunal Naik
RGRahul K. Goyal
Rahul K. Goyal
Luca FoschiniLuca Foschini
Luca Foschini
CCChoiwai Maggie Chak
Choiwai Maggie Chak
CTChristian Thielscher
Christian Thielscher
JGJogarao Gobburu
Jogarao Gobburu

16 June 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
QLQi Liu
Qi Liu
RHRuihao Huang
Ruihao Huang
JHJulie Hsieh
Julie Hsieh
HZHao Zhu
Hao Zhu
MTMo Tiwari
Mo Tiwari
SHShiew‐Mei Huang
Shiew‐Mei Huang

1 February 2013 in Int. Journal of Clinical Pharmacology and Therapeutics
Verified
Journal Article
Closed access
DWDemiana William-Faltaos
Demiana William-Faltaos
YCYing Chen
Ying Chen
YWYaning Wang
Yaning Wang
JGJogarao Gobburu
Jogarao Gobburu
HZHao Zhu
Hao Zhu
This research aimed to quantitatively describe the natural progression of Alzheimer's disease (AD) based on ADAScog scores in patients with mild-to-moderate AD. ADAS-cog data from 10 placebo-controlled clinical trials including more than 2,400 patients with up to 72 weeks of treatment were used. Different models describing the time course of ADAS-cog were evaluated. Patient characteristics potentially affect score changes were assessed. Furthermore, patient dropout patterns were characterized using parametric survival models. Covariate selection was performed to identify the risk factors associated with a higher dropout rate. ADAS-cog time course in mild-tomoderate AD patients receiving placebo was best described by a log-linear model, where the intercept represents the log-transformed ADAS-cog score at Week 10, the slope is the disease progression (i.e., natural increase of ADAS-cog score) on the log scale. Covariates influencing the intercept were baseline ADAS-cog score and baseline Mini Mental State Exam score. No covariates influenced the disease progression slope. A parametric log-normal model fit the dropout data best. Baseline ADAS-cog score and age were found to be significant predictors for dropout. AD disease and dropout models were both established. These models set up a quantitative basis for future clinical trial design and endpoint selection.

29 June 2021 in The Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
YBYouwei Bi
Youwei Bi
JLJiang Liu
Jiang Liu
FLFang Li
Fang Li
JYJingyu Yu
Jingyu Yu
ABAtul Bhattaram
Atul Bhattaram
YWYaning Wang
Yaning Wang
Model‐informed drug development (MIDD) has been a powerful and efficient tool applied widely in pediatric drug development due to its ability to integrate and leverage existing knowledge from different sources to narrow knowledge gaps. The dose selection is the most common MIDD application in regulatory submission related to pediatric drug development. This article aims to give an overview of the 3 broad categories of use of MIDD in pediatric dose selection: leveraging from adults to pediatric patients, leveraging from animals to pediatric patients, and integrating mechanism in infants and neonates. Population pharmacokinetic analyses with allometric scaling can reasonably predict the clearance in pediatric patients aged >5 years. A mechanistic‐based approach, such as physiologically based pharmacokinetic accounting for ontogeny, or an allometric model with age‐dependent exponent, can be applied to select the dose in pediatric patients aged ≤2 years. The exposure‐response relationship from adults or from other drugs in the same class may be useful in aiding the pediatric dose selection and benefit‐risk assessment. Increasing application and understanding of use of MIDD have contributed greatly to several policy developments in the pediatric field. With the increasing efforts of MIDD under the Prescription Drug User Fee Act VI, bigger impacts of MIDD approaches in pediatric dose selection can be expected. Due to the complexity of model‐based analyses, early engagement between drug developers and regulatory agencies to discuss MIDD issues is highly encouraged, as it is expected to increase the efficiency and reduce the uncertainty.

20 February 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
HZHao Zhu
Hao Zhu
MMMehul Mehta
Mehul Mehta
SHShiew‐Mei Huang
Shiew‐Mei Huang
YWYaning Wang
Yaning Wang
Click on the article title to read more.